Injectable lenacapavir for HIV prevention in Cape Town
Treatments studied
Part of Infections clinical trials.
This study tests a new injectable medication called lenacapavir to prevent HIV infection. You get to choose between different HIV prevention options, and the study will see how well the injection works for you.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must be 15 to 35 years old.
- You must test negative for HIV at the start of the study.
- You must weigh at least 35 kg (about 77 pounds).
- You need to live in the study area and be able to attend visits.
- You must be sexually active, meaning you've had at least 2 sexual encounters in the last 3 months.
- You must be willing to get an injectable form of HIV prevention.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study offers three ways to prevent HIV: a shot every two months (injectable PrEP), daily pills, or a vaginal ring. Researchers in Cape Town will help you choose the option that fits your life best.
This trial tests a new medication, lenacapavir, to see how well it works for preventing HIV. It is for people who want or need PrEP (a medicine to prevent HIV) and are interested in learning about different options.
This study offers a long-acting injectable form of PrEP (lenacapavir) to prevent HIV in Latine transgender women and gay men in the South. It aims to make HIV prevention easier by providing a shot instead of a daily pill.
This trial tests a new HIV prevention medicine called lenacapavir, given as a shot every six months. It's for young people at risk of HIV who haven't used PrEP before or have had gaps in their PrEP use.
This trial tests a long-acting injectable HIV prevention medication (cabotegravir) as an alternative to daily pills. It may be a good fit if you are a man who has sex with men and have been taking oral PrEP consistently.
This study tests a nurse-led program that offers a long-acting injectable medication (cabotegravir) to prevent HIV. The injection is given every two months, and the program aims to make it easier to access this prevention option at your local health center.
Hear when a new HIV trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.